HRP20210892T1 - Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv - Google Patents
Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv Download PDFInfo
- Publication number
- HRP20210892T1 HRP20210892T1 HRP20210892TT HRP20210892T HRP20210892T1 HR P20210892 T1 HRP20210892 T1 HR P20210892T1 HR P20210892T T HRP20210892T T HR P20210892TT HR P20210892 T HRP20210892 T HR P20210892T HR P20210892 T1 HRP20210892 T1 HR P20210892T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- ligand
- amino acid
- acid sequences
- variable region
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 26
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (9)
1. Ligand koji sadrži
- tri regije koje komplementarno određuju (CDRi) varijabilne regije lakog lanca (VL): CDR1, CDR2 i CDR3, odnosno izložene u SEQ ID Br. 1, SEQ ID Br. 2, SEQ ID Br. 3,
- tri CDRa varijabilne regije teškog lanca (VH): CDR4, CDR5 i CDR6, odnosno navedena u SEQ ID br. 4, SEQ ID br. 5 i SEQ ID br. 6,
pri čemu se navedeni ligand veže na anti-ligand koji se sastoji od aminokiselinske sekvence definirane SEQ ID Br. 20 ili SEQ ID Br. 32, a navedeni ligand je odabran iz skupine koja se sastoji od antitijela, scFv fragmenta i Fab fragmenta,
pri čemu je navedeni ligand namijenjen upotrebi u metodi liječenja.
2. Ligand koji sadrži
- tri komplementarno određujuće regije (CDRi) varijabilne regije lakog lanca (VL): CDR1, CDR2 i CDR3, odnosno izložene u SEQ ID Br. 1, SEQ ID Br. 2, SEQ ID Br. 3,
- tri CDRa varijabilne regije teškog lanca (VH): CDR4, CDR5 i CDR6, odnosno navedena u
SEQ ID br. 4, SEQ ID br. 5 i SEQ ID br. 6,
pri čemu se navedeni ligand veže na anti-ligand koji se sastoji od aminokiselinske sekvence definirane SEQ ID Br. 20 ili SEQ ID Br. 32, a navedeni ligand je odabran iz skupine koja se sastoji od antitijela, scFv fragmenta i Fab fragmenta,
pri čemu je navedeni ligand namijenjen upotrebi u metodi liječenja multiple skleroze.
3. Ligand za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je himerno ili humanizirano antitijelo.
4. Ligand za uporabu prema zahtjevu 3, naznačen time, da je navedeni ligand IgG.
5. Ligand za uporabu prema zahtjevu 4, naznačen time, da je navedeni ligand humani IgG1 ili IgG4.
6. Ligand za uporabu prema zahtjevu 5, naznačen time, da je navedeni ligand humanizirani IgG4 koji sadrži:
- varijabilnu regiju lakog lanca (VL) koja ima aminokiselinske sekvence navedene u SEQ ID br. 48, i
- varijabilnu regiju teškog lanca (VH) koja ima aminokiselinske sekvence navedene u SEQ ID br. 40.
7. Ligand za uporabu u skladu s patentnim zahtjevom 6, naznačen time što je navedeni ligand humanizirani IgG4 koji sadrži:
- laki lanac (LC) koji sadrži aminokiselinske sekvence navedene u SEQ ID br. 64, i
- teški lanac (HC) koji sadrži aminokiselinske sekvence navedene u SEQ ID br. 63.
8. Ligand koji sadrži:
- tri komplementarno određujuće regije (CDR) varijabilne regije lakog lanca (VL): CDR1, CDR2 i CDR3, odnosno izložene u SEQ ID Br. 1, SEQ ID Br. 2, SEQ ID Br. 3,
- tri CDR-a varijabilne regije teškog lanca (VH): CDR4, CDR5 i CDR6, odnosno navedena u SEQ ID br. 4, SEQ ID br. 5 i SEQ ID br. 6,
pri čemu se spomenuti ligand veže na anti-ligand koji se sastoji od aminokiselinske sekvence definirane SEQ ID br. 20 ili SEQ ID br. 32, a spomenuti ligand je humanizirano IgG4 antitijelo koje sadrži:
- varijabilnu regiju lakog lanca (VL) koja ima aminokiselinske sekvence navedene u SEQ ID br. 48, i
- varijabilnu regiju teškog lanca (VH) koja ima aminokiselinske sekvence navedene u SEQ ID br. 40.
9. Ligand prema zahtjevu 8, naznačen time, da je navedeni ligand humanizirano IgG4 antitijelo koje sadrži:
- laki lanac (LC) koji sadrži aminokiselinske sekvence navedene u SEQ ID br. 64, i
- teški lanac (HC) koji sadrži aminokiselinske sekvence navedene u SEQ ID br. 63.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12961308P | 2008-07-08 | 2008-07-08 | |
| US20258109P | 2009-03-13 | 2009-03-13 | |
| US21318909P | 2009-05-15 | 2009-05-15 | |
| EP17159699.2A EP3211005B1 (en) | 2008-07-08 | 2009-07-08 | Therapeutic use of specific ligand in msrv associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210892T1 true HRP20210892T1 (hr) | 2021-11-26 |
Family
ID=41165692
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171067TT HRP20171067T1 (hr) | 2008-07-08 | 2017-07-12 | Terapeutska upotreba specifičnih liganda u bolestima povezanim sa msrv |
| HRP20210892TT HRP20210892T1 (hr) | 2008-07-08 | 2021-06-04 | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171067TT HRP20171067T1 (hr) | 2008-07-08 | 2017-07-12 | Terapeutska upotreba specifičnih liganda u bolestima povezanim sa msrv |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US8715656B2 (hr) |
| EP (2) | EP2315777B1 (hr) |
| JP (3) | JP6058264B2 (hr) |
| KR (1) | KR101682040B1 (hr) |
| CN (1) | CN102143975B (hr) |
| AU (1) | AU2009268025B2 (hr) |
| BR (1) | BRPI0915667B8 (hr) |
| CA (1) | CA2729869C (hr) |
| CY (2) | CY1119185T1 (hr) |
| DK (1) | DK3211005T3 (hr) |
| EA (1) | EA024655B1 (hr) |
| ES (2) | ES2633965T3 (hr) |
| HK (2) | HK1158232A1 (hr) |
| HR (2) | HRP20171067T1 (hr) |
| HU (2) | HUE033803T2 (hr) |
| IL (1) | IL210204A (hr) |
| LT (2) | LT3211005T (hr) |
| MX (1) | MX2010014319A (hr) |
| NZ (1) | NZ590515A (hr) |
| PL (2) | PL2315777T3 (hr) |
| PT (2) | PT3211005T (hr) |
| SI (2) | SI2315777T1 (hr) |
| WO (1) | WO2010003977A1 (hr) |
| ZA (1) | ZA201100446B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2064325B1 (en) | 2006-09-01 | 2011-12-07 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| ES2633965T3 (es) * | 2008-07-08 | 2017-09-26 | Geneuro Sa | Uso terapéutico de ligando específico en enfermedades asociadas a MSRV |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| UA119032C2 (uk) | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
| EP2949342A1 (en) * | 2014-05-28 | 2015-12-02 | Geneuro SA | Antiretroviral drug targeting human endogenous retrovirus |
| SG11201802698XA (en) * | 2015-10-29 | 2018-05-30 | Hoffmann La Roche | Transgenic rabbit with common light chain |
| JP2018028538A (ja) * | 2016-08-12 | 2018-02-22 | 公立大学法人名古屋市立大学 | 統合失調症とその関連疾患の診断用マーカー及びその使用 |
| WO2019201908A1 (en) | 2018-04-17 | 2019-10-24 | Geneuro Sa | Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein |
| EP3916015A1 (en) * | 2020-05-28 | 2021-12-01 | Geneuro SA | Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases |
| CN113940993B (zh) * | 2021-12-20 | 2022-02-22 | 深圳万可森生物科技有限公司 | 一种鲈鱼弹状病毒g2-2m亚单位疫苗及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| DE69031711T2 (de) | 1989-08-09 | 1998-04-09 | Dekalb Genetics Corp | Methoden und zusammensetzungen für die herstellung von stabil transformierten, fruchtbaren mais pflanzen und zellen dafür |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| FR2734842B1 (fr) | 1995-06-02 | 1998-02-27 | Rhone Poulenc Agrochimie | Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides |
| FR2736926B1 (fr) | 1995-07-19 | 1997-08-22 | Rhone Poulenc Agrochimie | 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene |
| JP2003512844A (ja) * | 1999-10-28 | 2003-04-08 | ユニヴェルシテ・ドゥ・ジュネーブ | 多発性硬化症関連スーパー抗原 |
| RU2005137325A (ru) * | 2003-05-31 | 2006-09-10 | Микромет Аг (De) | Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам |
| FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
| CN111925445A (zh) | 2004-07-09 | 2020-11-13 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
| JP4088655B2 (ja) | 2004-09-06 | 2008-05-21 | キリンファーマ株式会社 | 抗ａ３３抗体 |
| US20090061485A1 (en) * | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
| US8475798B2 (en) | 2005-06-16 | 2013-07-02 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
| US7741448B2 (en) | 2005-06-21 | 2010-06-22 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
| FR2912314B1 (fr) * | 2007-02-09 | 2012-08-03 | Geneuro Sa | Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w. |
| ES2633965T3 (es) * | 2008-07-08 | 2017-09-26 | Geneuro Sa | Uso terapéutico de ligando específico en enfermedades asociadas a MSRV |
-
2009
- 2009-07-08 ES ES09780311.8T patent/ES2633965T3/es active Active
- 2009-07-08 EP EP09780311.8A patent/EP2315777B1/en active Active
- 2009-07-08 PL PL09780311T patent/PL2315777T3/pl unknown
- 2009-07-08 PL PL17159699T patent/PL3211005T3/pl unknown
- 2009-07-08 SI SI200931698T patent/SI2315777T1/sl unknown
- 2009-07-08 BR BRPI0915667A patent/BRPI0915667B8/pt active IP Right Grant
- 2009-07-08 HU HUE09780311A patent/HUE033803T2/en unknown
- 2009-07-08 PT PT171596992T patent/PT3211005T/pt unknown
- 2009-07-08 US US12/997,486 patent/US8715656B2/en active Active
- 2009-07-08 SI SI200932120T patent/SI3211005T1/sl unknown
- 2009-07-08 LT LTEP17159699.2T patent/LT3211005T/lt unknown
- 2009-07-08 CA CA2729869A patent/CA2729869C/en active Active
- 2009-07-08 HU HUE17159699A patent/HUE054712T2/hu unknown
- 2009-07-08 ES ES17159699T patent/ES2875762T3/es active Active
- 2009-07-08 DK DK17159699.2T patent/DK3211005T3/da active
- 2009-07-08 LT LTEP09780311.8T patent/LT2315777T/lt unknown
- 2009-07-08 EA EA201100160A patent/EA024655B1/ru unknown
- 2009-07-08 WO PCT/EP2009/058663 patent/WO2010003977A1/en active Application Filing
- 2009-07-08 NZ NZ590515A patent/NZ590515A/xx unknown
- 2009-07-08 AU AU2009268025A patent/AU2009268025B2/en active Active
- 2009-07-08 PT PT97803118T patent/PT2315777T/pt unknown
- 2009-07-08 CN CN200980134828.3A patent/CN102143975B/zh active Active
- 2009-07-08 MX MX2010014319A patent/MX2010014319A/es active IP Right Grant
- 2009-07-08 JP JP2011517153A patent/JP6058264B2/ja active Active
- 2009-07-08 KR KR1020117002937A patent/KR101682040B1/ko active IP Right Grant
- 2009-07-08 EP EP17159699.2A patent/EP3211005B1/en active Active
-
2010
- 2010-12-23 IL IL210204A patent/IL210204A/en active IP Right Grant
-
2011
- 2011-01-17 ZA ZA2011/00446A patent/ZA201100446B/en unknown
- 2011-11-25 HK HK11112831.5A patent/HK1158232A1/xx unknown
-
2014
- 2014-03-21 US US14/221,963 patent/US9550824B2/en active Active
-
2015
- 2015-03-11 JP JP2015048795A patent/JP6109869B2/ja active Active
-
2016
- 2016-12-02 US US15/367,864 patent/US9815888B2/en active Active
-
2017
- 2017-03-08 JP JP2017043877A patent/JP6495361B2/ja not_active Expired - Fee Related
- 2017-07-12 HR HRP20171067TT patent/HRP20171067T1/hr unknown
- 2017-07-20 CY CY20171100776T patent/CY1119185T1/el unknown
- 2017-10-26 US US15/794,541 patent/US10059758B2/en active Active
-
2018
- 2018-02-28 HK HK18102934.5A patent/HK1243436A1/zh unknown
-
2021
- 2021-06-02 CY CY20211100481T patent/CY1124281T1/el unknown
- 2021-06-04 HR HRP20210892TT patent/HRP20210892T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210892T1 (hr) | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv | |
| HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
| HRP20220405T1 (hr) | Protutijela protiv ngf i njihova upotreba | |
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| ES2605945T3 (es) | Anticuerpos de unión a Tweak | |
| HRP20180252T1 (hr) | Molekule humaniziranih antitijela specifični za il-31 | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| RS51334B (en) | CD20 Antibodies with Increased Binding Affinity for FC RECEPTOR AND EFFECTORY FUNCTION | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20020693B1 (hr) | HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß | |
| NZ703035A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2015521466A5 (hr) | ||
| JP2011509245A5 (hr) | ||
| HRP20131215T1 (hr) | Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope | |
| RU2014150433A (ru) | Улучшенные антитела антагонисты против gdf-8 и их применения | |
| NZ597996A (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas |